Literature DB >> 16197448

Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias.

Aihong Li1, Meredith A Goldwasser, Jianbiao Zhou, Scott A Armstrong, Hongjun Wang, Virginia Dalton, Jonathan A Fletcher, Stephen E Sallan, Lewis B Silverman, John G Gribben.   

Abstract

Infant acute lymphoblastic leukaemia (ALL) represents a rare but unique subset with poor prognosis. We analysed mixed-lineage leukaemia (MLL) gene rearrangements and the sequences of complete and incomplete immunoglobulin heavy chain gene rearrangements (IGH) in 14 infants (age < or = 12 months at diagnosis) enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. The dynamics of the leukaemic clone were followed during the course of the disease by quantitative real-time polymerase chain reaction of IGH rearrangements. Sixteen sequences were obtained from 13 (93%) of these infants. There was marked over usage of the V(H)6.1 gene segment (64%) in infants compared with older children with ALL (8%), (P < 0.001) and overusage of D(H)6 (P = 0.004) and J(H)1 (P = 0.004). Poor outcome was associated with MLL gene rearrangements rather than any specific V(H)D(H)J(H) gene usage patterns. Levels of minimal residual disease (MRD) at the end of induction appeared to be high in infants with ALL compared with older children, and although the number of infant cases studied was small, there were no differences in MRD levels after induction therapy in infant ALL with or without MLL gene rearrangements (P = 0.41) and quantitative MRD assessment at the early time points may not be predictive of outcome. Novel treatment strategies are required to improve the outcome in this poor prognosis subset of children with ALL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16197448     DOI: 10.1111/j.1365-2141.2005.05754.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  1 in total

1.  Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.

Authors:  Janine Stutterheim; Inge M van der Sluis; Paola de Lorenzo; Julia Alten; Philip Ancliffe; Andishe Attarbaschi; Benoit Brethon; Andrea Biondi; Myriam Campbell; Giovanni Cazzaniga; Gabriele Escherich; Alina Ferster; Rishi S Kotecha; Birgitte Lausen; Chi Kong Li; Luca Lo Nigro; Franco Locatelli; Rolf Marschalek; Claus Meyer; Martin Schrappe; Jan Stary; Ajay Vora; Jan Zuna; Vincent H J van der Velden; Tomasz Szczepanski; Maria Grazia Valsecchi; Rob Pieters
Journal:  J Clin Oncol       Date:  2021-01-06       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.